ADVANCE MY CLINICAL TREATMENTS

Interpatient heterogeneity makes it difficult to find the first suitable patient to dose.
Turbine's answer

Simulations of complex cellular signaling networks to predict DDR inhibitor synthetic lethal opportunities marking patient with the highest chance to benefit

We need to maximize our asset's likelihood of success by finding the right eligibility criteria for clinical trials.
Turbine's answer

Novel ideas for synergistic combination therapies across modalities

Early identification of potential resistance mechanisms can reduce late-stage failure rates.
Turbine's answer

Drug assays in heterogeneous populations of cancer cell avatars with representation of alterations driving acquired resistance

BENEFITS ONLY TURBINE PROVIDES

Broader clinical search space by generating unique patient representative avatars
Patient relevant testable and actionable biomarker hypotheses to  guide the next stage of benchtop therapeutic research
Mechanistic link between drug and biomarkers to ensure that the therapeutic effects in preclinical models are more likely to be replicated in clinical settings.
4
4 months from AI training to ranked hypotheses
218
218 drug – gene alteration combination tested in 301  patient derived in silico avatars
28
Predicted 28 significant disease subtype associated biomarkers

    Close